Less than a year after its introduction in Europe, Celltrion’s Remsima SC subcutaneous infliximab biosimilar has captured material market share among inflammatory bowel disease patients in the EU5 countries, including the UK, according to a newly-released report sampling nearly 250 EU5 gastroenterologists in November and December last year.
Celltrion’s Remsima SC Biosimilar Starts Strong In EU5 Countries
New Study Follows Approval For IBD Indications Last Year
Celltrion is capitalizing on the earlier strength of its intravenous Remsima formulation to make waves with its innovative subcutaneous version, according to the results of a new study sampling nearly 250 gastroenterologists in EU5 countries.
More from Biosimilars
• By
After Amgen’s surprise launch of the first US biosimilar to Eylea last year, expectations around competition are being further upended with the news that Biocon Biologics has struck a settlement deal with Regeneron allowing it to launch its own aflibercept rival in the second half of 2026. Will other challengers follow suit?
• By
News of a fresh US investigation into the pharma sector has sparked renewed concerns over the impact that US trade tariffs would have on the generics and biosimilars industry. The AAM has responded with a warning over the potential effects on shortages and access, while Medicines for Europe has proposed five key action areas to bolster the sector in Europe.
• By
Having failed in US patent litigation over Amgen’s Enbrel, Sandoz is taking an alternative approach in trying to get its Erelzi biosimilar to market in the US ahead of patent expiry in 2029: launching an antitrust attack against the originator for “unlawfully extending and entrenching its monopoly."
• By
After having its facility cleared by the FDA earlier in the year, Biocon Biologics finally saw its bevacizumab biosimilar receiving approval in the US.
More from Products
• By
After having its facility cleared by the FDA earlier in the year, Biocon Biologics finally saw its bevacizumab biosimilar receiving approval in the US.
• By
The US Senate Judiciary Committee’s Chairman Chuck Grassley criticized the Senate’s reduced working hours as six previously introduced bills once again land on their desk.
• By
Jazz has agreed a nine figure settlement agreement in the US with purchasers of its Xyrem blockbuster following claims that it illegally delayed generic competition to the blockbuster treatment for narcolepsy via patent-litigation settlement agreements with several ANDA sponsors.